Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
about
Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situIntegration of molecular profiling and chemical imaging to elucidate fibroblast-microenvironment impact on cancer cell phenotype and endocrine resistance in breast cancerMining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer.Evolutionary dynamics of intratumor heterogeneity.Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis.Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas.PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasisProgression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia.Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.Breast cancer with neoductgenesis: histopathological criteria and its correlation with mammographic and tumour features.Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study.RNA-Seq of human breast ductal carcinoma in situ models reveals aldehyde dehydrogenase isoform 5A1 as a novel potential target.Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers.Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.Expression of Cancer/Testis genes in ductal carcinoma in situ and benign lesions of the breast.Meeting report from the second EurocanPlatform summer school on translational cancer research, Portugal, 20-24 October 2014.Designing vaccines to prevent breast cancer recurrence or invasive disease.Circulating prolactin and in situ breast cancer risk in the European EPIC cohort: a case-control study.The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.TODRA, a lncRNA at the RAD51 Locus, Is Oppositely Regulated to RAD51, and Enhances RAD51-Dependent DSB (Double Strand Break) Repair.Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signalingOpportunities for molecular epidemiological research on ductal carcinoma in-situ and breast carcinogenesis: interdisciplinary approaches.Different Biological Action of Oleic Acid in ALDHhigh and ALDHlow Subpopulations Separated from Ductal Carcinoma In Situ of Breast Cancer.Epithelial cells captured from ductal carcinoma in situ reveal a gene expression signature associated with progression to invasive breast cancerA Molecular Portrait of High-Grade Ductal Carcinoma In Situ.Clinicopathological predictive factors for ipsilateral and contralateral events following initial surgery to treat ductal carcinoma in situPreclinical HER-2 Vaccines: From Rodent to Human HER-2Predictors of Recurrent Ductal Carcinoma In Situ after Breast-Conserving SurgeryRepositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions.Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell linesEffective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort.DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival.Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.Progression from ductal carcinoma in situ to invasive breast cancer: revisited.Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.Ductal carcinoma in situ - update on risk assessment and management.Cell Polarity Proteins in Breast Cancer Progression.p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer.Genome evolution in ductal carcinoma in situ: invasion of the clones.
P2860
Q26864448-B0EE42A6-786C-477C-894B-F8FF4ED26573Q28538685-5016057D-BDB3-47E9-B05B-DEF7D8B3E238Q33618065-EEBB01D6-FBA3-4B42-B447-AC7C3F5B61BFQ33867413-EE8C64FB-BF0B-473D-8FA2-E6DCD676B274Q33873665-B702E891-7070-4478-AD6D-89183E677188Q33980589-DD471FC5-6D4D-4029-8419-3DFD0A069B8BQ34038395-8F2B3B75-8FF0-4C79-8540-88675C3F4A48Q34088976-B5AF2664-FF3D-4F6F-A365-1EFD01C721DCQ34196315-3332CFB9-0702-4785-9D25-A2DC5AAADB23Q34454213-01DA3467-300F-4F89-9C2B-E8C6DB89FF69Q34493998-4B503627-123E-451A-BD0F-7C96489E8442Q34510318-E7218040-F031-493E-BC60-6B9CFF6CCD3CQ34576614-CAD00D51-409E-4BA3-9B6D-06D60C1AED62Q34664892-70C66094-5D5E-4165-B516-E008A6359559Q34971907-A0FBAA64-512A-407E-932E-F4906B09A652Q35106168-CBBF8A73-EC56-49F5-B1AC-7EF82455324CQ35546337-C7B80E67-7B89-440D-89DA-5FFEDCA80C8DQ35549885-A6822B49-D915-433E-A05F-1319D7C208EBQ35660389-4350B8C5-716E-4A50-8579-A7F76B12B8C5Q35731289-ADCD143F-1A8D-4AF6-B851-B2259B3C3D74Q35779345-BE6B8CE4-E042-413E-AD0D-560BE4BAAD20Q36023456-74705396-E909-4D12-9FE7-17FB86F23C26Q36121716-E4430ADC-81CE-4C86-8C45-353F882BF478Q36154351-442EC05C-3ACC-403A-ACD8-3464434F496FQ36622366-735B62C7-F3AB-4A73-AD4B-186F92609AA2Q36820188-92193C56-7D30-486B-A25F-5EA7EDE9B6DFQ36914661-06F7BCC5-662A-4127-823D-177F3C8C58C7Q37056933-D87F8BF9-9A6F-42B9-B0A8-12930D41D4FBQ37091483-EB6A5003-500C-4472-B9D3-1BCD8413E0ACQ37103526-8D35C015-41DD-4005-8ADF-1A8C37E1053FQ37362912-95A8BA78-EEEA-4B00-B787-172963033796Q37670843-36678EBD-0AFC-4636-B4FC-EC07750A4086Q37702047-C8303CBF-118A-4052-BCDB-C163DD4B9325Q37805245-0930DB5F-2547-4D13-A2DC-BE01CAF1C3DDQ38124521-2060EFD2-546A-464E-900A-51728C866B43Q38327185-03061598-F4A7-44B2-B791-44DC43C05E63Q38696796-628A9193-DBA6-4900-9B78-40D9D56E1F46Q38881927-78FC73CA-1A89-4024-A31F-2C1C5B01BC60Q38884681-358AF062-3C54-4A64-ABA4-038AD496CF4EQ39012815-01076010-5053-4614-98A4-9A4D50F7647E
P2860
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
@en
type
label
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
@en
prefLabel
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
@en
P2093
P2860
P50
P1433
P1476
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
@en
P2093
Johan Botling
Michael Hallett
Rose-Marie Amini
Simin Tahmasebpoor
Wenjing Zhou
P2860
P304
P356
10.1016/J.MOLONC.2010.06.007
P50
P577
2010-06-26T00:00:00Z